Financial Update

Research Update

Research funded during the third quarter of 2016

Project/Researcher & Distribution Amount

Impact of Inflammasome Deactivation on Alzheimer’s Disease
Vishwa Deep Dixit, D.V.M., Ph.D., Yale School of Medicine
Impact of Inflammasome Deactivation on Alzheimer’s Disease
Vishwa Deep Dixit, D.V.M., Ph.D., Yale School of Medicine

Early Role of Microglia in Synapse Loss in Alzheimer’s Disease
Beth Stevens, Ph.D., Children’s Hospital Boston

A 3-D Human Neural Cell Culture System for Studying Neuron-Microglia Interaction in Alzheimer’s Disease
Hansang Cho, Ph.D., University of North Carolina at Charlotte

Role of Blood-Brain Barrier Function in Alzheimer’s Disease Pathogenesis
Se Hoon Choi, Ph.D., Massachusetts General Hospital, and Roger Kamm, Ph.D., Massachusetts Institute of Technology

3-D Neural Culture/High-Throughput Drug Screening for Alzheimer’s Disease
Doo Yeon Kim, Ph.D., Massachusetts General Hospital

Search for Female-Specific Genetic Factors Contributing to Risk for Alzheimer’s Disease
Rudy Tanzi, Ph.D., Massachusetts General Hospital

Use of High-Content Drug Screening and Systems Biology Modeling on a Novel 3-D Cell Model to Repurpose Known Drugs for Alzheimer’s Disease
Stephen Wong, Ph.D., Houston Methodist Research Institute

3DSS: Alzheimer’s Disease Drug Discovery in 3-D
Weiming Xia, Ph.D., Boston University

SORLA Attenuates Abeta Toxicity Through Interactions With EphA4
Huaxi Xu, Ph.D., Sanford Burnham Prebys Medical Discovery Institute

Nanobodies to Cross the Blood-Brain Barrier
Bart De Strooper, M.D., Ph.D., and Maarten Dewilde, Ph.D., VIB Center for the Biology of Disease

Development of Novel APP Dimerization Inhibitors That Lower Abeta Levels
Carmela Abraham, Ph.D., Boston University

Uncovering Determinants of Neuronal Vulnerability in Alzheimer’s Disease
Paul Greengard, Ph.D., The Rockefeller University

Binding Site Characterization of a Novel Pyridazine-Derived Class of γ-Secretase Modulators
Steven Wagner, Ph.D., University of California, San Diego

BIN1 in Alzheimer’s Disease Neuropathology
Gopal Thinakaran, Ph.D., University of Chicago

G2T Research Models and Materials
Taconic Biosciences

Total Distributed to Research for Q3 2016
$3,448,431

*Numbers shown are preliminary for the period and are rounded to the nearest $100,000.

Cure Alzheimer’s Fund

Mission
Fund research with the highest probability of preventing, slowing or reversing Alzheimer’s disease.

Research Consortium
Rudolph E. Tanzi, Ph.D., Chairman, Research Consortium; Harvard Medical School/Massachusetts General Hospital
Ben A. Barres, M.D., Ph.D., Stanford University
Bart De Strooper, M.D., Ph.D., Vlaams Instituut voor Biotechnologie
Murali Doraiswamy, M.D., Duke University
Karen Duff, Ph.D., Columbia University
Sam Gandy, M.D., Ph.D., Jaco School of Medicine at Mount Sinai
Christian Haass, M.D., Ludwig-Maximilians-Universität München
David Michael Holtzman, M.D., Washington University, St. Louis
Richard L. Huganir, Ph.D., The Johns Hopkins University
Nancy Ip, Ph.D., The Hong Kong University of Science and Technology
Bruce Lamb, Ph.D., Indiana University
Christoph Lange, Ph.D., Harvard T.H. Chan School of Public Health
Virginia M.-Y. Lee, Ph.D., University of Pennsylvania
Roberto Malinow, M.D., Ph.D., University of California, San Diego
Eric E. Schmidt, Ph.D., Jaco School of Medicine at Mount Sinai
Sangram S. Sisodia, M.D., Ph.D., University of Chicago
Li-Huei Tsai, Ph.D., The Picower Institute, MIT
Robert Vassar, Ph.D., Northwestern University
Steven L. Wagner, Ph.D., University of California, San Diego
Berislav Zlokovic, M.D., Ph.D., University of Southern California

Cure Alzheimer’s Fund
34 Washington St., Suite 200
Wellesley Hills, MA 02481
Telephone: 877-CURE-ALZ (287-3259)
Fax: 781-658-2399
curealz.org
Centre City Tower
650 Smithfield St., Suite 2015
Pittsburgh, PA 15222
Telephone: 412-261-2785

Scientific Advisory Board
Dennis Choi, M.D., Ph.D., Chairman, Scientific Advisory Board, Stony Brook University
Caleb Finch, Ph.D., University of Southern California
Paul Greengard, Ph.D., The Rockefeller University
Vince Grillo, Ph.D., University of Michigan
John S. Lazo, Ph.D., University of Virginia
Robert C. Malenka, M.D., Ph.D., Stanford University
John C. Mazziotta, M.D., Ph.D., UCLA
William Mobley, M.D., Ph.D., University of California, San Diego
Ronald C. Petersen, M.D., Ph.D., Mayo Clinic
Thomas C. Sudhof, M.D., Stanford University

Board of Directors
Henry F. McCance*, Lake Wales, Fla., Co-Chairman
Jeffrey L. Morris*, Key Largo, Fla., Co-Chairman
Tim Armour, Wellesley Hills, Mass., President
Robert F. Greenhill*, Key Largo, Fla., Senior Vice President, Development
Madeleine Adelson, Marketing Manager
Joyce Cantow, Accounting Assistant
Barbara Chambers, Senior Engagement Officer
Emily Franke, intern
Cindy-jo Gross, Special Projects
Laurel Lyle, Director of Fundraising Programs
Jessica Mutch, Chief Financial Officer
Sally Rosenfield, Senior Vice President
David Shenk, Senior Adviser
John R. Slattery Jr., Senior Vice President, Development
Meg Smith, Senior Adviser, Strategy and Special Projects
Connor Swan, Development Associate
Nancy Thome, Bookkeeper

*Founder

CH 53-2396428

Contributing Writer: Patty Bovie
Copy Editor: Colleen O’Neill
Design: Winking Fish

Charity Designation
Cure Alzheimer’s Fund® is a “doing business as” name for the Alzheimer’s Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-2396428.